All news

Inhibikase holds $4.75 analyst target, trades near

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

Inhibikase Therapeutics (NASDAQ:IKT) carries a "Moderate Buy" consensus from analysts with an average 12-month price target of $4.75. The clinical-stage biopharmaceutical company, developing treatments for neurological diseases including Parkinson's, reported a quarterly loss of $0.11 per share that missed estimates. Shares opened at

Read original source

IKT company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.